JSTOR Daily

Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand

Background. In Thailand, phase 1/2 trials of monovalent subtype B and bivalent subtype B/E (CRFO1_AE) recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were ...
JSTOR Daily

HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1-Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 ...

The first trial of the efficacy of a human immunodeficiency virus (HIV)-l vaccine was conducted in North America and The Netherlands between 1998 and 2003. This multicenter, randomized, ...
Nature

Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier

More than 40% of HIV infections occur via female reproductive tract (FRT) through heterosexual transmission. Epithelial cells that line the female genital mucosa are the first line of defense against ...
Nature

HIV gp120- and methamphetamine-mediated oxidative stress induces astrocyte apoptosis via cytochrome

HIV-1 glycoprotein 120 (gp120) is known to cause neurotoxicity via several mechanisms including production of proinflammatory cytokines/chemokines and oxidative stress. Likewise, drug abuse is thought ...
Monthly Prescribing Reference

NDA Submitted for Potential First-in-Class HIV Therapy

The New Drug Application (NDA) for fostemsavir (ViiV Healthcare), a first-in-class HIV-1 attachment inhibitor for the treatment of HIV-1 infection, has been submitted to the Food and Drug ...